Curated News
By: NewsRamp Editorial Staff
June 08, 2026

Tonix Pharmaceuticals Expands TONMYA Access to 52M Commercial Lives

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Tonix Pharmaceuticals expanded TONMYA coverage to 52 million commercial lives, boosting market access and competitive position.
  • Tonix secured a second group purchasing organization agreement for TONMYA, effective June 1, 2026, adding 17 million covered lives.
  • Expanded TONMYA coverage provides a new non-opioid fibromyalgia treatment option to millions, improving patient care and reducing opioid reliance.
  • TONMYA is the first new fibromyalgia treatment in over 15 years, offering a sublingual bedtime analgesic for long-term use.

Impact - Why it Matters

This expansion means millions of fibromyalgia patients now have access to a new, non-opioid treatment option, potentially reducing opioid dependency and improving pain management. The coverage agreement with a second major group purchasing organization signals growing insurer confidence in TONMYA, which could pave the way for broader adoption and further research into its use for other conditions like depression and stress disorders.

Summary

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced a new coverage agreement with a second major group purchasing organization, set to take effect on June 1, 2026. This agreement expands access to TONMYA® for an additional 17 million U.S. commercial lives, bringing the total commercial coverage for its fibromyalgia treatment to approximately 52 million lives. This represents about 29% of the estimated 177 million commercially insured individuals in the United States. Additionally, TONMYA is now available through Medicaid programs covering approximately 75 million lives, while discussions with Medicare continue. TONMYA is a non-opioid analgesic designed for daily bedtime administration and long-term use, launched commercially following an earlier coverage agreement in May that provided access to approximately 35 million commercial lives.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure also supports its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. The pipeline also includes TNX-2900 for Prader-Willi syndrome and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500 for kidney transplant rejection prevention.

This news matters because it highlights a significant expansion in patient access to TONMYA, providing a new non-opioid option for fibromyalgia sufferers. With chronic pain affecting millions, the availability of TONMYA through major insurers and Medicaid could reduce reliance on opioids and improve quality of life for patients. Tonix's ongoing research into additional indications further underscores the potential broader impact of this treatment.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals Expands TONMYA Access to 52M Commercial Lives

blockchain registration record for this content.